Topic: Monkeypox Vaccine

Dr. Robert Malone's explanation for the sudden Mpox emergency declaration is featured, suggesting it was timed to prevent the previous declaration from expiring. The hosts play a clip of the WHO clarifying that Mpox is "not the new COVID," which Curry interprets as a walkback following public skepticism and a push for vaccine funding in Africa.

The CDC issued warnings regarding a rise in monkeypox cases, which have nearly doubled compared to last year. Additionally, a rare and more deadly strain of bacterial meningitis is increasing, with 422 cases reported in 2023. Health officials are encouraging high-risk individuals and middle-aged adults to stay up to date on vaccinations for both illnesses.

The CDC has issued a warning about a potential resurgence of Mpox (formerly monkeypox) this summer, following a cluster of new cases in Chicago. Many of the new cases occurred in individuals who were already fully vaccinated, leading to concerns about waning immunity. The majority of cases continue to be reported among men who have sex with men.

The CDC is encouraging "fractional dosing" of monkeypox vaccines to stretch limited supplies as cases rise among men who have sex with men, particularly in Black and Brown communities. Officials are also warning that the virus can spread through contaminated bedding and towels, leading to increased demand for the vaccine at major public events.

Dr. Ashish Jha addresses questions regarding whether childhood smallpox vaccinations provide protection against the current monkeypox outbreak, stating the data is still being reviewed. The discussion touches on the physical scars left by historical smallpox vaccines and the current uncertainty regarding immunity levels in older populations. The FDA's role in monitoring the spread and developing testing methods is also noted.

Reports emerge of individuals contracting monkeypox despite receiving their first vaccine dose, leading to new guidance on the necessity of multiple shots. Health experts suggest a "sliding scale" of protection that requires several weeks and a second dose to reach maximum efficacy. The segment compares the shifting timelines for monkeypox vaccines to the evolving requirements seen during the COVID-19 rollout.

The FDA issued an emergency use authorization allowing the monkeypox vaccine to be delivered subcutaneously at one-fifth of the standard dose to stretch limited supplies. This "dose-sparing" strategy is based on a single study, raising concerns among patients about its actual effectiveness. The change from intramuscular to under-the-skin injection is criticized as an experimental move on the public without sufficient data.

Documents suggest that the Jynneos vaccine, originally intended for smallpox, had monkeypox added to its indication in 2019 at the request of U.S. government stakeholders. The timing of this regulatory change occurs three years prior to the current outbreak, raising questions about government foresight or corruption.

Long lines for the monkeypox vaccine have formed in San Francisco as the city struggles with limited supply. Members of the local gay community report high levels of concern and a proactive approach to vaccination, drawing parallels to historical health crises. Public health officials aim to distribute thousands of doses weekly to high-risk individuals.

ABC News Chief Medical Correspondent Dr. Jennifer Ashton detailed the transmission risks of monkeypox, emphasizing skin-to-skin contact and contaminated materials like towels. While not classified strictly as a sexually transmitted disease, the virus spreads through prolonged intimate contact. The JYNNEOS vaccine, originally approved in 2019, is being deployed despite questions regarding its specific efficacy against the current strain.

Global manufacturing capacity for the monkeypox vaccine is limited, with millions of doses previously discarded due to expiration. There is speculation that pharmaceutical companies like Pfizer or Moderna may develop mRNA-based solutions to address the shortage. The discussion explores whether the current health emergency will be used to further validate mRNA technology despite ongoing debates over COVID-19 vaccine performance.

Tim Nguyen of the World Health Organization discusses the global supply of monkeypox vaccines, including the MVA-BN and ACAM2000 stockpiles. He emphasizes that the effectiveness of these vaccines in the current context is uncertain and recommends they be delivered within clinical trial frameworks. Concerns are raised regarding whether individuals receiving the shots are fully informed of their experimental status in this specific application.

Quebec health officials reported that monkeypox cases have doubled, leading to the administration of smallpox vaccines to high-risk contacts. The discussion explores the demographic spread of the virus and questions whether the symptoms are being confused with shingles or vaccine adverse events. Most cases are reported to be mild with patients expected to recover.